MHRA nod for Bayer’s Beyonttra for ATTR-CM

26 April 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Beyonttra (acoramidis), from Germany’s Bayer (BAYN: DE), to treat adult patients with cardiomyopathy (damage to the heart muscle) caused by variant or wild-type transthyretin amyloidosis (ATTR-CM).
Acoramidis has been approved via a fast-track approval process for medicines, known as the International Recognition Procedure (IRP), following approval by the European Medicines Agency (EMA) earlier this year.

Developed by US genetic diseases and cancer drug company BridgeBio Pharma (Nasdaq: BBIO), Beyonttra was licensed to Bayer to commercialize acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe.

Market potential and competition

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK